About the journal
Advances in Hematology is an open-access journal published by Wiley in United Kingdom, publishing in english. It is listed in DOAJ according to the sources read. Declared publication charge: 950 USD. Declared review time at DOAJ: 15 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Wiley
- ISSN
- 1687-9104 · 1687-9112
- Country
- United Kingdom
- Languages
- english
- Access
- Open access
- Declared publication charge
- 950 USD
- Articles in DOAJ
- 406
- Declared review time
- 15 weeks
- Declared peer-review model
- peer_review
- Official website
- https://onlinelibrary.wiley.com/journal/3793
Index listings
- DOAJ · 2009-04-30
- Indexing
- DOAJ
- APC
- 950 USD
- Declared review time (DOAJ)
- 15 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
406
Most recent article
last month
Average review time (journal-declared via DOAJ)
15weeks
Works in OpenAlex
416
Last recorded publication year
2026
h-index
49
i10-index
225
From OpenAlex open data (CC0).
Editorial & policy13
- Last DOAJ review date
- 2026-03-12
- Added to DOAJ
- 2009-04-30
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPMCPortico
- Observed digital preservation (Keepers registry)— snapshot 2026-09-21
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 95%
- ORCID iDs in current deposits
- 95%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 101504271
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Hemoglobinopathies and Related Disorders
- Hemoglobinopathies and Related Disorders
- Lymphoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Iron Metabolism and Disorders
- Iron Metabolism and Disorders
- Chronic Lymphocytic Leukemia Research
- Chronic Lymphocytic Leukemia Research
Show all subjects (50)
- Blood groups and transfusion
- Blood groups and transfusion
- Acute Myeloid Leukemia Research
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplantation
- Erythrocyte Function and Pathophysiology
- Erythrocyte Function and Pathophysiology
- Immune Cell Function and Interaction
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Blood transfusion and management
- Platelet Disorders and Treatments
- Blood transfusion and management
- T-cell and B-cell Immunology
- T-cell and B-cell Immunology
- Venous Thromboembolism Diagnosis and Management
- Venous Thromboembolism Diagnosis and Management
- Neonatal Health and Biochemistry
- Blood donation and transfusion practices
- Neonatal Health and Biochemistry
- Blood donation and transfusion practices
- Atrial Fibrillation Management and Outcomes
- Erythropoietin and Anemia Treatment
- CAR-T cell therapy research
- Atrial Fibrillation Management and Outcomes
- Erythropoietin and Anemia Treatment
- CAR-T cell therapy research
- Zebrafish Biomedical Research Applications
- Zebrafish Biomedical Research Applications
Keywords (DOAJ)
- lymphoma
- erythrocytes
- haematology
- leukaemia
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ